Remove Clinical Trials Remove Cosmetics Remove Dermatology
article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. Daxxify is effective, as safe as competitors, and has been well tolerated in clinical trials.

Botox 98
article thumbnail

Renuvion Dermal Handpiece by Apyx Medical Gets FDA Clearance for Wrinkle Reduction

XTalks

XTALKS WEBINAR: Diversity and Inclusion in Clinical Trials — Practical Steps for Patient Recruitment Strategies. Register for this free webinar to learn about the practical steps to be taken towards diversity and inclusion in clinical trials. The trial included 55 subjects over the age of 30 with a wrinkle score of ?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Understanding Atopic Dermatitis, Its Symptoms & Treatment

Olympian Clinical Research

At OCR we’re committed to educating the public and raising awareness about diseases like eczema, so today we’re taking some time to walk you through everything you need to know about this common dermatology condition. Triggers can vary patient by patient, but some of the most common eczema triggers are: Cosmetic products. Fragrances.

article thumbnail

Vapogenix Awarded $1.5M Phase II SBIR Grant to Develop Groundbreaking Topical Therapy for Painful Inflammatory Conditions

The Pharma Data

VPX638 formulation for painful inflammatory conditions is among Vapogenix’s platform of novel, patented formulations of VAs, being developed for the localized treatment of a broad range of painful conditions, including wounds, combat-related injuries, and medical procedures such as needle injections, needle biopsies and cosmetic dermatology.

article thumbnail

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

The Pharma Data

associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. “For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects.

Trials 52
article thumbnail

SkinVive by Juvéderm: The New Dermal Filler Coming to the US

XTalks

It’s an extremely important factor I consider in my therapeutic process of restoring their natural beauty and appearance,” said Macrene Alexiades, MD, PhD, dual US-EU board-certified dermatologist, SkinVive by Juvéderm lead investigator and author of the clinical trial published in Dermatologic Surgery.

Filler 92
article thumbnail

Letybo Earns FDA Approval, Hugel Expands Its Global Aesthetic Market Leadership

XTalks

RELATED: Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. 134 How Does Letybo Work?